PPARγ and wnt signaling in adipogenic and osteogenic differentiation of mesenchymal stem cells

Current Stem Cell Research and Therapy

Volumn 11, Issue 3, 2016, Pages 216-225

  Yuan, Zongyi ^a   Li, Qing ^a   Luo, Shihong ^a   Liu, Zhi ^a   Luo, Daowen ^a   Zhang, Bo ^a   Zhang, Dongdong ^a   Rao, Pengcheng ^a   Xiao, Jingang ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Adipocyte differentiation; Mesenchymal stem cells; MicroRNA; Osteoblast differentiation; Peroxisome proliferatoractivated receptor ; Regenerative therapy; Wnt signaling

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN EPSILON; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN; WNT1 PROTEIN; WNT10B PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN; WNT7A PROTEIN; WNT8A PROTEIN; WNT8B PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; RUNX2 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOGENESIS; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; DOWN REGULATION; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; IMMUNE RESPONSE; INSULIN SENSITIVITY; MESENCHYMAL STEM CELL; OSTEOBLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSACTIVATION; WNT SIGNALING PATHWAY; BONE MARROW CELL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ADIPOCYTES; ADIPOGENESIS; BETA CATENIN; BONE MARROW CELLS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MESENCHYMAL STROMAL CELLS; MICRORNAS; OSTEOBLASTS; OSTEOGENESIS; PPAR GAMMA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84961721892     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X10666150519093429     Document Type: Review

References (129)

1. Yang N, Wang G, Hu C, et al. Tumor necrosis factor alpha suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J Bone Miner Res 2013; 28(3): 559-73.
2. Adler RA. Osteoporosis in men: a review. Bone Res 2014; 2: 14001.
3. Adami S, Idolazzi L, Fracassi E, et al. Osteoporosis Treatment: When to Discontinue and When to Re-start. Bone Res 2013; 1(4): 323-35.
4. Pillai HK, Fang M, Beglov D, et al. Ligand binding and activation of PPARgamma by Firemaster(R) 550: effects on adipogenesis and osteogenesis in vitro. Environ Health Perspect 2014; 122(11): 1225-32.
5. Rozen WM, Ashton MW, Pan WR, et al. Anatomical variations in the harvest of anterolateral thigh flap perforators: a cadaveric and clinical study. Microsurgery 2009; 29(1): 16-23.
6. van de Vyver M, Andrag E, Cockburn IL, et al. Thiazolidinedioneinduced lipid droplet formation during osteogenic differentiation. J Endocrinol 2014; 223(2): 119-32.
7. Cho ES, Kim MK, Son YO, et al. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells 2012; 33(2): 173-81.
8. Yamashita A, Takada T, Nemoto K, et al. Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage. FEBS Lett 2006; 580(17): 4121-5.
9. Lee MJ, Chen HT, Ho ML, et al. PPARgamma silencing enhances osteogenic differentiation of human adipose-derived mesenchymal stem cells. J Cell Mol Med 2013; 17(9): 1188-93.
10. Hassumi MY, Silva-Filho VJ, Campos-Junior JC, et al. PPARgamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol 2009; 9(10): 1150-8.
11. Henjes F, Lourido L, Ruiz-Romero C, et al. Analysis of autoantibody profiles in osteoarthritis using comprehensive protein array concepts. J Proteome Res 2014; 13(11): 5218-29.
12. Shen J, Li S, Chen D. TGF-beta signaling and the development of osteoarthritis. Bone Res 2014; 2: 14016.
13. Okubo M, Okada Y. [Destruction of the articular cartilage in osteoarthritis]. Clin Calcium 2013; 23(12): 1705-13.
14. Zhang X, Zhu J, Liu F, et al. Reduced EGFR signaling enhances cartilage destruction in a mouse osteoarthritis model. Bone Res 2014; 2: 14015.
15. Sampson S, Botto-van Bemden A, Aufiero D. Autologous bone marrow concentrate: review and application of a novel intraarticular orthobiologic for cartilage disease. Phys Sportsmed 2013; 41(3): 7-18.
16. Granchi D, Devescovi V, Baglio SR, et al. Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone 2010; 46(3): 780-8.
17. Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012; 120(9): 1933-41.
18. Lim MH, Ong WK, Sugii S. The current landscape of adiposederived stem cells in clinical applications. Expert Rev Mol Med 2014; 16: e8.
19. Lin Y, Wang T, Wu L, et al. Ectopic and in situ bone formation of adipose tissue-derived stromal cells in biphasic calcium phosphate nanocomposite. J Biomed Mater Res A 2007; 81(4): 900-10.
20. Wu L, Cai X, Dong H, et al. Serum regulates adipogenesis of mesenchymal stem cells via MEK/ERK-dependent PPARgamma expression and phosphorylation. J Cell Mol Med 2010; 14(4): 922-32.
21. Xiao J, Wu Y, Chen R, et al. Expression of Pcp4 gene during osteogenic differentiation of bone marrow mesenchymal stem cells in vitro. Mol Cell Biochem 2008; 309(1-2): 143-50.
22. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100(9): 1249-60.
23. Takada I, Kouzmenko AP, Kato S. Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies. Expert Opin Ther Targets 2009; 13(5): 593-603.
24. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19(2): 179-92.
25. Chen JR, Lazarenko OP, Wu X, et al. Obesity reduces bone density associated with activation of PPARgamma and suppression of Wnt/beta-catenin in rapidly growing male rats. PLoS One 2010; 5(10): e13704.
26. Almeida M, Ambrogini E, Han L, et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009; 284(40): 27438-48.
27. Gustafson B, Smith U. Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem 2010; 285(18): 14031-41.
28. D'Alimonte I, Lannutti A, Pipino C, et al. Wnt signaling behaves as a "master regulator" in the osteogenic and adipogenic commitment of human amniotic fluid mesenchymal stem cells. Stem Cell Rev 2013; 9(5): 642-54.
29. McGregor RA, Choi MS. microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med 2011; 11(4): 304-16.
30. Berendsen AD, Olsen BR. Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology. Cell Mol Life Sci 2014; 71(3): 493-7.
31. He X, Eberhart JK, Postlethwait JH. MicroRNAs and micromanaging the skeleton in disease, development and evolution. J Cell Mol Med 2009; 13(4): 606-18.
32. Fakhry M, Hamade E, Badran B, et al. Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts. World J Stem Cells 2013; 5(4): 136-48.
33. Kim M, Kim C, Choi YS, et al. Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: implication to age-associated bone diseases and defects. Mech Ageing Dev 2012; 133(5): 215-25.
34. Lian JB, Stein GS, van Wijnen AJ, et al. MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 2012; 8(4): 212-27.
35. Lisse TS, Adams JS, Hewison M. Vitamin D and microRNAs in bone. Crit Rev Eukaryot Gene Expr 2013; 23(3): 195-214.
36. TheinHan W, Liu J, Tang M, et al. Induced pluripotent stem cellderived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements. Bone Res 2013; 1(4): 371-84.
37. Grottkau BE, Lin Y. Osteogenesis of Adipose-Derived Stem Cells. Bone Res 2013; 1(2): 133-45.
38. Xiao J, Yang X, Jing W, et al. Adipogenic and osteogenic differentiation of Lin(-)CD271(+)Sca-1(+) adipose-derived stem cells. Mol Cell Biochem 2013; 377(1-2): 107-19.
39. Lin Y, Tang W, Wu L, et al. Bone regeneration by BMP-2 enhanced adipose stem cells loading on alginate gel. Histochem Cell Biol 2008; 129(2): 203-10.
40. Grottkau BE, Yang X, Zhang L, et al. Comparison of Effects of Mechanical Stretching on Osteogenic Potential of ASCs and BMSCs. Bone Res 2013; 1(3): 282-90.
41. Baghaban Eslaminejad M, Malakooty Poor E. Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. World J Stem Cells 2014; 6(3): 344-54.
42. Lin Y, Luo E, Chen X, et al. Molecular and cellular characterization during chondrogenic differentiation of adipose tissue-derived stromal cells in vitro and cartilage formation in vivo. J Cell Mol Med 2005; 9(4): 929-39.
43. Zhou C, Cai X, Fu Y, et al. Tetraploid complementation proves pluripotency of induced pluripotent stem cells derived from adipose tissue. Cell Prolif 2015; 48(1): 39-46.
44. Davies BM, Morrey ME, Mouthuy PA, et al. Repairing damaged tendon and muscle: are mesenchymal stem cells and scaffolds the answer? Regen Med 2013; 8(5): 613-30.
45. Salamon A, Toldy E. [Use of mesenchymal stem cells from adult bone marrow for injured tissue repair]. Orv Hetil 2009; 150(27): 1259-65.
46. Wu L, Cai X, Zhang S, et al. Regeneration of articular cartilage by adipose tissue derived mesenchymal stem cells: perspectives from stem cell biology and molecular medicine. J Cell Physiol 2013; 228(5): 938-44.
47. Cai X, Lin Y, Ou G, et al. Ectopic osteogenesis and chondrogenesis of bone marrow stromal stem cells in alginate system. Cell Biol Int 2007; 31(8): 776-83.
48. Tella SH, Gallagher JC. Biological agents in management of osteoporosis. Eur J Clin Pharmacol 2014; 70(11): 1291-301.
49. Almario RU, Karakas SE. Roles of Circulating WNT-Signaling Proteins and WNT-Inhibitors in Human Adiposity, Insulin Resistance, Insulin Secretion, and Inflammation. Horm Metab Res 2014.
50. Yang X, Cai X, Wang J, et al. Mechanical stretch inhibits adipogenesis and stimulates osteogenesis of adipose stem cells. Cell Prolif 2012; 45(2): 158-66.
51. Fu N, Yang X, Ba K, et al. Low-intensity pulsed ultrasound induced enhanced adipogenesis of adipose-derived stem cells. Cell Prolif 2013; 46(3): 312-9.
52. Kawai M, Sousa KM, MacDougald OA, et al. The many facets of PPARgamma: novel insights for the skeleton. Am J Physiol Endocrinol Metab 2010; 299(1): E3-9.
53. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009; 5(8): 442-7.
54. Byun MR, Kim AR, Hwang JH, et al. FGF2 stimulates osteogenic differentiation through ERK induced TAZ expression. Bone 2014; 58: 72-80.
55. Azzolin L, Zanconato F, Bresolin S, et al. Role of TAZ as mediator of Wnt signaling. Cell 2012; 151(7): 1443-56.
56. Dong S, Yang B, Guo H, et al. MicroRNAs regulate osteogenesis and chondrogenesis. Biochem Biophys Res Commun 2012; 418(4): 587-91.
57. Corona JC, Duchen MR. PPARgamma and PGC-1alpha as Therapeutic Targets in Parkinson's. Neurochem Res 2014.
58. Lefterova MI, Haakonsson AK, Lazar MA, et al. PPARgamma and the global map of adipogenesis and beyond. Trends Endocrinol Metab 2014; 25(6): 293-302.
59. Chen YC, Wu JS, Tsai HD, et al. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol Neurobiol 2012; 46(1): 114-24.
60. Kim TH, Kim MY, Jo SH, et al. Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications. Yonsei Med J 2013; 54(3): 545-59.
61. Takada I, Kouzmenko AP, Kato S. PPAR-gamma Signaling Crosstalk in Mesenchymal Stem Cells. PPAR Res 2010; 2010.
62. Wei X, Li G, Yang X, et al. Effects of bone morphogenetic protein-4 (BMP-4) on adipocyte differentiation from mouse adiposederived stem cells. Cell Prolif 2013; 46(4): 416-24.
63. Floyd ZE, Stephens JM. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARgamma. Biochim Biophys Acta 2012; 1822(7): 1090-5.
64. Patel JJ, Butters OR, Arnett TR. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem Funct 2014; 32(4): 368-77.
65. Li G, Fu N, Yang X, et al. Mechanical compressive force inhibits adipogenesis of adipose stem cells. Cell Prolif 2013; 46(5): 586-94.
66. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17(1): 9-26.
67. Maung SM, Jenny A. Planar cell polarity in Drosophila. Organogenesis 2011; 7(3): 165-79.
68. Miller RK, Hong JY, Munoz WA, et al. Beta-catenin versus the other armadillo catenins: assessing our current view of canonical Wnt signaling. Prog Mol Biol Transl Sci 2013; 116: 387-407.
69. Lin GL, Hankenson KD. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 2011; 112(12): 3491-501.
70. Scott EL, Brann DW. Estrogen regulation of Dkk1 and Wnt/beta-Catenin signaling in neurodegenerative disease. Brain Res 2013; 1514: 63-74.
71. Kozinski K, Dobrzyn A. [Wnt signaling pathway--its role in regulation of cell metabolism]. Postepy Hig Med Dosw (Online) 2013; 67: 1098-108.
72. James RG, Conrad WH, Moon RT. Beta-catenin-independent Wnt pathways: signals, core proteins, and effectors. Methods Mol Biol 2008; 468: 131-44.
73. Wang Y, Li YP, Paulson C, et al. Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) 2014; 19: 379-407.
74. Spreafico A, Tentler JJ, Pitts TM, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 2013; 19(15): 4149-62.
75. Yamashita T, Uehara S, Udagawa N, et al. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways. PLoS One 2014; 9(1): e85878.
76. Zhang WB, Zhong WJ, Wang L. A signal-amplification circuit between miR-218 and Wnt/beta-catenin signal promotes human adipose tissue-derived stem cells osteogenic differentiation. Bone 2014; 58: 59-66.
77. Velasco J, Zarrabeitia MT, Prieto JR, et al. Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int 2010; 21(1): 109-18.
78. Rossini M, Gatti D, Adami S. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 2013; 93(2): 121-32.
79. Maupin KA, Droscha CJ, Williams BO. A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice. Bone Res 2013; 1(1): 27-71.
80. Malhotra D, Yang Y. Wnts' fashion statement: from body stature to dysplasia. Bonekey Rep 2014; 3: 541.
81. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135(5): 825-37.
82. Korvala J, Juppner H, Makitie O, et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet 2012; 13: 26.
83. De A. Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai) 2011; 43(10): 745-56.
84. Chang J, Sonoyama W, Wang Z, et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 2007; 282(42): 30938-48.
85. Okamoto M, Udagawa N, Uehara S, et al. Noncanonical Wnt5a enhances Wnt/beta-catenin signaling during osteoblastogenesis. Sci Rep 2014; 4: 4493.
86. Gomez-Orte E, Saenz-Narciso B, Moreno S, et al. Multiple functions of the noncanonical Wnt pathway. Trends Genet 2013; 29(9): 545-53.
87. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012; 18(3): 405-12.
88. Bilkovski R, Schulte DM, Oberhauser F, et al. Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem 2010; 285(9): 6170-8.
89. Pan S, Yang X, Jia Y, et al. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-g expression. J Cell Physiol 2014; 229(5): 631-9.
90. Ling HY, Wen GB, Feng SD, et al. MicroRNA-375 promotes 3T3-L1 adipocyte differentiation through modulation of extracellular signal-regulated kinase signalling. Clin Exp Pharmacol Physiol 2011; 38(4): 239-46.
91. Kim YJ, Kim HJ, Chung KY, et al. Transcriptional activation of PIK3R1 by PPARgamma in adipocytes. Mol Biol Rep 2014; 41(8): 5267-72.
92. Ling HY, Ou HS, Feng SD, et al. CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009; 36(9): e32-9.
93. Li H, Chen X, Guan L, et al. MiRNA-181a regulates adipogenesis by targeting tumor necrosis factor-alpha (TNF-alpha) in the porcine model. PLoS One 2013; 8(10): e71568.
94. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58(5): 1050-7.
95. Yi C, Xie WD, Li F, et al. MiR-143 enhances adipogenic differentiation of 3T3-L1 cells through targeting the coding region of mouse pleiotrophin. FEBS Lett 2011; 585(20): 3303-9.
96. Chen L, Dai YM, Ji CB, et al. MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. Mol Cell Endocrinol 2014; 393(1-2): 65-74.
97. Viladomiu M, Hontecillas R, Pedragosa M, et al. Modeling the role of peroxisome proliferator-activated receptor gamma and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS One 2012; 7(10): e47525.
98. Kang T, Lu W, Xu W, et al. MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells. J Biol Chem 2013; 288(48): 34394-402.
99. Lin Q, Gao Z, Alarcon RM, et al. A role of miR-27 in the regulation of adipogenesis. Febs j 2009; 276(8): 2348-58.
100. Chen L, Cui J, Hou J, et al. A novel negative regulator of adipogenesis: microRNA-363. Stem Cells 2014; 32(2): 510-20.
101. Roberto VP, Tiago DM, Silva IA, et al. MiR-29a is an enhancer of mineral deposition in bone-derived systems. Arch Biochem Biophys 2014; 564: 173-83.
102. Zuo B, Zhu JF, Li J, et al. microRNA-103a functions as a mechnosensitive microRNA to inhibit bone formation through targeting Runx2. J Bone Miner Res 2014.
103. Wen X, Cawthorn WP, MacDougald OA, et al. The influence of Leucine-rich amelogenin peptide on MSC fate by inducing Wnt10b expression. Biomaterials 2011; 32(27): 6478-86.
104. Graneli C, Karlsson C, Brisby H, et al. The effects of PPARgamma inhibition on gene expression and the progression of induced osteogenic differentiation of human mesenchymal stem cells. Connect Tissue Res 2014; 55(4): 262-74.
105. Grunberg JR, Hammarstedt A, Hedjazifar S, et al. The Novel Secreted Adipokine WNT1-inducible Signaling Pathway Protein 2 (WISP2) Is a Mesenchymal Cell Activator of Canonical WNT. J Biol Chem 2014; 289(10): 6899-907.
106. Hammarstedt A, Hedjazifar S, Jenndahl L, et al. WISP2 regulates preadipocyte commitment and PPARgamma activation by BMP4. Proc Natl Acad Sci USA 2013; 110(7): 2563-8.
107. Shang YC, Wang SH, Xiong F, et al. Wnt3a signaling promotes proliferation, myogenic differentiation, and migration of rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin 2007; 28(11): 1761-74.
108. Hoshiba T, Kawazoe N, Tateishi T, et al. Development of stepwise osteogenesis-mimicking matrices for the regulation of mesenchymal stem cell functions. J Biol Chem 2009; 284(45): 31164-73.
109. Laudes M. Role of WNT signalling in the determination of human mesenchymal stem cells into preadipocytes. J Mol Endocrinol 2011; 46(2): R65-72.
110. Perobner I, Karow M, Jochum M, et al. LRP6 mediates Wnt/betacatenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells. Int J Biochem Cell Biol 2012; 44(11): 1970-82.
111. Bloom DC, Giordani NV, Kwiatkowski DL. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 2010; 1799(3-4): 246-56.
112. Ge W, Liu Y, Chen T, et al. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1. Biomaterials 2014; 35(23): 6015-25.
113. Kim MB, Song Y, Kim C, et al. Kirenol inhibits adipogenesis through activation of the Wnt/beta-catenin signaling pathway in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2014; 445(2): 433-8.
114. Lee YH, Kim SH, Lee YJ, et al. Transcription factor Snail is a novel regulator of adipocyte differentiation via inhibiting the expression of peroxisome proliferator-activated receptor gamma. Cell Mol Life Sci 2013; 70(20): 3959-71.
115. Sun J, Wang Y, Li Y, et al. Downregulation of PPARgamma by miR-548d-5p suppresses the adipogenic differentiation of human bone marrow mesenchymal stem cells and enhances their osteogenic potential. J Transl Med 2014; 12: 168.
116. Kang BY, Park KK, Green DE, et al. Hypoxia mediates mutual repression between microRNA-27a and PPARgamma in the pulmonary vasculature. PLoS One 2013; 8(11): e79503.
117. Zhang JF, Fu WM, He ML, et al. MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol 2011; 8(5): 829-38.
118. Taniguchi M, Nakajima I, Chikuni K, et al. MicroRNA-33b downregulates the differentiation and development of porcine preadipocytes. Mol Biol Rep 2014; 41(2): 1081-90.
119. Qin L, Chen Y, Niu Y, et al. A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics 2010; 11: 320.
120. Wang J, Guan X, Guo F, et al. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. Cell Death Dis 2013; 4: e845.
121. Chen H, Wang S, Chen L, et al. MicroRNA-344 inhibits 3T3-L1 cell differentiation via targeting GSK3beta of Wnt/beta-catenin signaling pathway. FEBS Lett 2014; 588(3): 429-35.
122. Ko JY, Chuang PC, Chen MW, et al. MicroRNA-29a ameliorates glucocorticoid-induced suppression of osteoblast differentiation by regulating beta-catenin acetylation. Bone 2013; 57(2): 468-75.
123. Li H, Li T, Wang S, et al. miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Stem Cell Res 2013; 10(3): 313-24.
124. de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 2009; 184(1): 83-99.
125. Nemoto E, Ebe Y, Kanaya S, et al. Wnt5a signaling is a substantial constituent in bone morphogenetic protein-2-mediated osteoblastogenesis. Biochem Biophys Res Commun 2012; 422(4): 627-32.
126. Wang Q, Cai J, Cai XH, et al. miR-346 regulates osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by targeting the Wnt/beta-catenin pathway. PLoS One 2013; 8(9): e72266.
127. Zhang J, Tu Q, Bonewald LF, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res 2011; 26(8): 1953-63.
128. Tamura M, Uyama M, Sugiyama Y, et al. Canonical Wnt signaling activates miR-34 expression during osteoblastic differentiation. Mol Med Rep 2013; 8(6): 1807-11.
129. Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 2012; 287(50): 42084-92.